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Introduction: Systemic and topical nasal decongestants are widely used in otorhinolaryngology
and general practice for the management of acute rhinosinusitis and as an adjuvant in cer-
tain forms of chronic rhinosinusitis. These products, very effective to rapidly improve nasal
congestion, are sometimes available over the counter and can be the subject of misuse, which
is difﬁcult to control. The Société Franc¸aise d’ORL has recently issued guidelines concerning
the use of these decongestants in the doctor’s ofﬁce and the operating room.
Materials and methods: The review of the literature conducted by the task force studied in
detail the concepts of ‘‘rebound congestion’’ and ‘‘rhinitis medicamentosa’’ often reported in a
context of misuse, particularly of topical nasal decongestants. The clinical and histopathological
consequences of prolonged and repeated use of nasal decongestants have been studied on
animal models and healthy subjects.
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Results: Discordant results have been obtained, as some authors reported a harmful effect of
nasal decongestants on the nasal mucosa, while others did not identify any signiﬁcant changes.
No study has been able to distinguish between inﬂammatory lesions induced by chronic rhinos-
inusitis and lesions possibly related to the use of nasal decongestants.
Discussion: The task force explained the rebound congestion observed after stopping nasal
decongestant treatment by return of the nasal congestion induced by rhinosinusitis and rejected
the concept of rhinitis medicamentosa in the absence of scientiﬁc evidence from patients with
rhinosinusitis.
Conclusion: Nasal decongestants are recommended for the management of acute rhinosinusitis
to reduce the consequences of often disabling nasal congestion. They are also recommended
during rhinoscopic examination and for preparation of the nasal mucosa prior to endonasal
surgery.








































































treatment with oxymetazoline in healthy subjects [13].
Several studies by Graf also described rebound congestion.ntroduction
asal congestion is the symptom most commonly reported
uring acute and chronic rhinosinusitis. The prevalence of
asal congestion in the population is estimated to be 30% [1].
egardless of its origin, nasal congestion severely affects
uality of life by its impact on daily life, especially sleep,
ork or school and social life [2]. It has been estimated,
n the United States, that allergic rhinitis is responsible for
bout 800,000 days off work and 825,000 days away from
chool and decreased productivity for 4,250,000 days per
ear [3].
Systemic and topical nasal decongestants are recom-
ended for the symptomatic treatment of nasal congestion
uring acute nasopharyngeal diseases in subjects over the
ge of 15. Many products are available in France (Table 1).
heir efﬁcacy has been clearly demonstrated in clinical
ractice [4]. This remarkable efﬁcacy on nasal conges-
ion is the basis for frequently inappropriate prescription
enewals and excessive self-prescribed medication, espe-
ially as these products are available over the counter.
isuse of nasal decongestants can be accentuated by the
act that some of them are included in over-the-counter oral
xed combinations with other drug substances (cetirizine,
aracetamol, ibuprofen).
Rare but sometimes serious adverse reactions have been
escribed, often related to overdose [5,6]. Central neuro-
ogical effects essentially consist of headache, seizures and
troke [7]. Cardiovascular adverse reactions include hyper-
ensive crisis, tachycardia or palpitations [8,9]. ‘‘Rebound
ongestion’’ and ‘‘rhinitis medicamentosa’’ are terms very
requently used in the literature to describe the con-
equences of misuse of nasal decongestants, especially
opical products. These terms are therefore often used
o describe persistent symptoms of nasal congestion in
atients who have repeatedly used nasal decongestants. In
linical practice, the diagnostic criteria of these concepts
f ‘‘rebound congestion’’ and ‘‘rhinitis medicamentosa’’
evertheless remain very vague. Rebound congestion refers
o the highly subjective clinical criterion of nasal congestion
hat can be used to designate blocked nose, stufﬁness or
nﬂammation. Rhinitis medicamentosa also raises diagnos-
ic problems, as it can be confused with the rebound effect





tThe Société Franc¸aise d’ORL issued consensual clinical
ractice guidelines on the use of nasal decongestants in
ctober 2011. Based on the methodology published by the
aute Autorité de la santé (French National Authority for
ealth) in 2006, these guidelines were elaborated by a task
orce and were then validated by a scoring group. A detailed
nalysis of the literature reviewed the concepts of rebound
ongestion and rhinitis medicamentosa. The present review
s therefore designed to clarify these two entities in order
o determine their diagnostic relevance in clinical practice.
ebound effect of topical decongestants
eﬁnition
ccording to the authors who described this effect, rebound
ongestion is deﬁned by deterioration of the feeling of nasal
ongestion for which topical nasal decongestants were ini-
ially prescribed during repeated use or after stopping this
reatment [10,11]. The term ‘‘rebound congestion’’ was
sed for the ﬁrst time in 1944 by Feinberg and Friedlaen-
er to describe the nasal congestion experienced after the
se of naphazoline [12]. However, this concept of rebound
ongestion remains very controversial. The literature con-
erning this concept is contradictory, raising a doubt about
he real existence of this effect. Published studies that have
ried to demonstrate rebound congestion by measuring nasal
esistance were conducted in healthy subjects preventing
xtrapolation of the results to patients with rhinosinusitis.
vidence in favour of rebound congestion
his potential action of topical nasal decongestants has been
bserved in several studies, all conducted in healthy sub-
ects using various methods of evaluation. Morris et al.
bserved an increase of nasal resistance after 3 days ofn a study on 18 healthy subjects treated with oxymeta-
oline 50g per day or xylometazoline 280g per day for
0 days, the author demonstrated the presence of mucosal
edema on rhinostereometry (optical measurement of the











Table 1 List of products and their indications in France in 2012. Topical nasal decongestants are usually marketed in ﬁxed combinations. Imidazoles are only used in topical
nasal decongestants, including some ofﬁce medicine products containing prednisolone.






Adrenaline Adrenaline AGT or
REN
IV / IM / SC / nasal List I
Hydroxyamphetamine Not marketed
Phenylephrine Hexarhume Biclotymol + Chlorpheniramine Oral 30mg / 2mg > 15 years None
Humoxal SOL
nasale
Benzalkonium Chloride Nasal spray 6mg > 15 years List II
Tuaminoheptane Rhinoﬂuimucil Acetylcysteine + Benzalkonium
chloride




Benzoic acid Nasal spray 0.04 g > 15 years List II
Phenylpropanolamine Not marketed
Pseudoephedrine Actifed LP rhin all Cetirizine Oral 5mg > 15 years None





Oral 500mg / 25mg > 15 years None
Adviltab rhume Ibuprofen Oral 200 mg > 15 years None
Cequinyl Paracetamol + ascorbic acid Oral 250mg / 50mg > 15 years None
Doli rhume Paracetamol Oral 500 mg > 15 years None
Dolirhumepro Paracetamol /
paracetamol + doxylamine
Oral 500mg / 7.5mg > 15 years None
Humex rhinite
allergique
Cetirizine Oral 10mg > 16 years None
Humex rhume Paracetamol / Chlorpheniramine Oral 500mg / 4mg > 15 years None
Nurofen rhume Ibuprofen Oral 200mg > 15 years None
Rhinadvil Ibuprofen Oral 200mg > 15 years None
Rhinureﬂex Ibuprofen Oral 200 mg > 15 years None
Rhumagrip Paracetamol Oral 500mg > 15 years None




Naphazoline Derinox Prednisolone Nasal Spray 20mg / 100mL > 15 years List II
Xylocaïne
naphazolinee
Lidocaine hydrochloride Nasal drops 500mg / 100mL > 6 years List II
Oxymetazoline Aturgyl Nasal Spray > 15 years List II
Deturgylone Prednisolone Nasal Spray > 15 years List I
Pernazene Nasal Spray > 15 years List II
Tramazoline Not marketed
Clonazoline Not marketed
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Figure 1 Pathophysiological hypotheses for the rebound effect of nasal decongestants: a: the oedema responsible for the nasal
congestion experienced by the patient could be caused by mucosal ischaemia induced by intense stimulation of arteriolar 2
adrenergic receptors (R2) by nasal decongestants leading to prolonged vasoconstriction; b: the other hypothesis consists of a






































Eumber of functional receptors after mucosal, arteriolar and v
enous plexuses responsible for oedema.
hich continued to worsen until the 30th day. This effect
as not worsened by increasing the dosage of nasal decon-
estants, but by the presence of benzalkonium chloride in
he preparation [10]. In a study conducted in 19 healthy sub-
ects treated with oxymetazoline 200g three times daily
or 17 days, Vaidyanathan et al. showed a signiﬁcant reduc-
ion of peak inspiratory ﬂow and a non-signiﬁcant increase
f inspiratory nasal resistance measured by anterior rhi-
omanometry compared to the measurements performed
n these same subjects before treatment [11]. Akerlund
nd Bende also described rebound congestion, but failed
o demonstrate any increase of nasal resistance on rhino-
anometry after treatment with xylometazoline in healthy
ubjects [14].
From a pathophysiological point of view, the vascular
etwork of the nasal mucosa can be divided into resis-
ance vessels (arterioles) and capacitance vessels (venous
lexus) surrounded by sympathetic nerve ﬁbres innervat-
ng − and -adrenergic receptors. -adrenergic receptors
re predominant in the nasal mucosa and stimulation of
hese receptors induces vasoconstriction. The vasomotor
ctivity of capacitance vessels is regulated by both 1
nd 2 receptors, while that of resistance vessels is reg-
lated by 2 receptors. Nasal decongestants mimic the
ction of noradrenaline on 1 and 2 receptors, either
irectly by stimulating the receptor or indirectly by induc-
ng the release of noradrenaline from storage vesicles
15].
Two pharmacobiological hypotheses (Fig. 1) have been
ormulated on the basis of these studies in healthy subjects
o explain rebound congestion:
I
i
ws internalization, inducing relative congestion of the sinusoid
hypothesis 1: this effect may be due to ischaemia of
the nasal mucosa; stimulation of 2 receptors induces
intense vasoconstriction of submucosal arterioles [16].
This ischaemia would predispose to the development of
interstitial oedema [17,18] (Fig. 1a);
hypothesis 2: the number of membrane  adrener-
gic receptors would be decreased by downregulation
and endogenous noradrenaline production would be
decreased by presynaptic negative feedback. These
effects would induce relative dilatation of the submucosal
sinusoid venous plexuses due to loss of dynamic venous
vasoconstriction [17,19,20] (Fig. 1b). Adrenergic recep-
tors could also become refractory to nasal decongestants,
causing the patient to increase the doses of nasal decon-
gestants (tachyphylaxis) [16,21]. This phenomenon would
be associated with decreased sensitivity to endogenous
catecholamines [19], especially affecting 1 receptors
[22].
The results of these studies in favour of the rebound
ffect of decongestants cannot be directly extrapolated to
linical practice, as they were conducted in healthy subjects
n whom the nasal mucosa is not subjected to the cytokine
nvironment associated with inﬂammation.
vidence against rebound congestiont is difﬁcult to extrapolate the results of the above stud-
es to clinical practice, as inﬂamed nasal mucosa treated






















































oNasal decongestants: Rebound congestion and rhinitis medic
absorption properties as healthy nasal mucosa. Evaluation
of the congestion possibly induced by a topical nasal decon-
gestant is consequently biased by the underlying disease.
A review of the literature also reveals a similar number
of studies, also conducted in healthy subjects that failed
to demonstrate any rebound effect of decongestants. For
example, Yoo et al. did not observe this phenomenon after
4 weeks of treatment with oxymetazoline 200g in the
evening in 10 healthy subjects [23]. Watanabe et al. also did
not observe any modiﬁcation of inspiratory nasal ﬂow after 4
weeks of treatment with oxymetazoline 200g 3 times daily
in 30 healthy subjects [24]. Petruson and Hansson reached
similar conclusions based on rhinomanometric analysis of 20
healthy subjects treated with oxymetazoline 150g three
times daily for 6 weeks [25].
Finally, clinical experience shows that rebound conges-
tion is not observed in most patients despite prolonged
self-prescribed use of topical nasal decongestants without
dose escalation. However, these clinical observations do
not eliminate the need for nasal decongestant prescribing
rules, as their possible harmful effects cannot be formally
excluded.
The task force’s conclusions after evaluation by
the scoring group
The rebound effect of topical decongestants, i.e. increased
nasal resistance after stopping treatment, has only been
described experimentally in healthy subjects. The ‘‘rebound
congestion’’ classically described in patients, i.e. recur-
rence or deterioration of nasal congestion after stopping
treatment, could actually correspond to persistence of the
disease initially justifying prescription of the decongestant.
The rebound effect of topical nasal decongestants
described in the literature in healthy subjects has not been
studied in patients with rhinosinusitis.
Rhinitis medicamentosa
Deﬁnition
The term ‘‘rhinitis medicamentosa’’ is used in the
English language literature to describe persistent rhinitis
induced by prolonged use of topical nasal decongestants
(sympathomimetic amines and imidazoles) [21]. Rhini-
tis medicamentosa usually occurs following an episode
of acute viral rhinitis and is characterized by persis-
tent nasal congestion, usually isolated, and occurring
increasingly rapidly after application of nasal decongestants
[20]. This congestion causes the patient to increase the fre-
quency of application and the quantity applied, resulting
in dependence on topical nasal decongestants [17]. Clini-
cal rhinoscopic examination is non-speciﬁc, showing areas
of red, thickened mucosa and dull zones [21].
The harmful effects of prolonged treatment by topical
nasal decongestants on the nasal mucosa have also been
described in animal models and in healthy subjects. As
for rebound congestion, it is difﬁcult to extrapolate these






valuation on animal models
ublished studies on the mucosal effects of nasal decon-
estants are relatively old and were conducted in animal
odels [26]. A ﬁrst report, published in 1947, on rabbits
reated four times daily with intranasal 1% ephedrine or
aphazoline, showed loss of ciliated cells on D5, epithelial
esions at 1 week, oedema at 2 weeks, epithelial hyper-
rophy with ﬁbrosis at 3 weeks, complete disorganization
f the mucosal architecture at 5 weeks and squamous cell
etaplasia of the respiratory mucosa with vascular sclero-
is at 8 weeks [20,27]. Using a rabbit model, Talaat el al
ompared the normal nasal mucosa and the nasal mucosa
reated with 1% ephedrine after 2 weeks and 3 weeks.
rchitectural disorganization of the ciliary axoneme, loss of
ntercellular junctions and submucosal oedema with colla-
en inﬁltration were observed on electron microscopy after
weeks of treatment. Reduction of the number of cili-
ted cells and thickening of the basement membrane were
bserved after 3 weeks [28]. An analysis of the effects
f 0.05% naphazoline administered three times daily to
uinea-pigs sacriﬁced at regular intervals revealed similar
bnormalities after 2 weeks of treatment with an ini-
ial increase of mucosal cells followed by loss of these
ells starting at 6 weeks. Immunohistochemical analysis
howed increased cholinesterase activity on periglandular
erve ﬁbres, suggesting a reduction of the parasympa-
hetic response to nasal decongestants [29]. More recently,
uh et al. evaluated the effects of nasal decongestants
y comparing three groups of 30 rabbits treated with
henylephrine, oxymetazoline or saline for 1, 2 or 4 weeks.
ub-mucosal oedema and loss of cilia on ulcerated respira-
ory epithelium were observed after 2 weeks of treatment
n the two groups treated with nasal decongestants. These
esions were more severe at 4 weeks. In the phenylephrine
roup, features of purulent acute sinusitis were observed in
our rabbits and six rabbits after 2 and 4 weeks, respectively.
he authors attributed this infectious complication to alter-
tion of the mucosa barrier due to destruction of ciliated
ells [30].
valuation in humans
he results observed in man are less convincing, preven-
ing any valid conclusions concerning the possible harmful
ffects of topical nasal decongestants on the nasal mucosa.
urthermore, when oedema was described in patients
reated with topical nasal decongestants, it is often unclear
hether rhinoscopy had been performed in these patients
efore inclusion in the study to eliminate preexisting
inonasal disease.
A study in 20 healthy adults treated with xylometazo-
ine three times daily (0.75mg) for 6 weeks did not reveal
ny morphological changes of the mucosa, basement mem-
rane or lamina propria [25,31,32]. Five of these 20 patients
eveloped acute viral rhinosinusitis during the study with-
ut any epithelial abnormalities attributable to treatment
25,31,32]. In 2004, Lin et al. compared the nasal mucosa of
ight adult patients with non-allergic chronic rhinitis, eight
atients with symptoms suggestive of nasal decongestant














































































































he clinical criteria used to include these eight patients with
hinitis medicamentosa. Microscopic examination demon-
trated epithelial metaplasia with epithelial hyperplasia,
oss of ciliated cells and an increase of mucus-secreting cells
nd submucosal glands in the nasal decongestant group [31].
nother study in eight healthy adults did not reveal any sig-
iﬁcant mucosal oedema after 10 days of treatment with
xymetazoline 0.05mg three times daily with poor reac-
ivity on the histamine provocation test [17]. In contrast,
edema measured by rhinostereometry was described after
0 days of use of this nasal decongestant with deterio-
ation of oedema after application of histamine [33—36].
istological abnormalities (destruction of ciliated cells,
rteriolar dilatation, mucus-secreting cell hyperplasia) were
escribed by Wang and Bu in 30 adults treated with
aphazoline and presenting symptoms suggestive of rhini-
is medicamentosa [37]. Knipping et al. reported similar
ndings in 22 patients with a history of topical nasal
econgestant use for more than 6 months compared to 10
on-treated control subjects. Light microscopy revealed loss
f ciliated cells, thickening of the epithelial basement mem-
rane, and submucosal perivascular oedema [38].
re the histological lesions allegedly induced by
opical nasal decongestants reversible?
o published clinical study has described the natural history
f the epithelial lesions observed after stopping prolonged
se of topical nasal decongestants. Various authors have also
mphasized the difﬁculty of describing lesions speciﬁcally
nduced by topical nasal decongestants when these lesions
ccur in a context of preexisting rhinosinusitis, as the under-
ying disease prevents reliable baseline assessment of the
asal mucosa [20].
Studies on the prolonged use of topical nasal decon-
estants have essentially focussed on the reversibility of
linical signs and the treatment modalities useful for nasal
econgestant withdrawal. These studies also did not deﬁne
igorous diagnostic criteria (clinical or histological) for the
iagnosis of rhinitis medicamentosa. The nasal congestion
escribed in these studies could therefore be attributed
o nasal decongestants or to the presence of concomi-
ant rhinitis. Several studies have highlighted the efﬁcacy
f topical corticosteroids to relieve the congestion expe-
ienced by these patients. A randomized, double-blind,
lacebo-controlled study in 19 healthy subjects treated
ith oxymetazoline 200g three times daily for 14 days
howed that nasal congestion resolved after administra-
ion of ﬂuticonasone 200g twice daily for 3 days, despite
ontinued use of the nasal decongestant [11]. The authors
uggested that this effect was due to increased expres-
ion of -adrenergic receptors induced by corticosteroids,
hereby eliminating the tachyphylaxis effect of nasal decon-
estants (rapid internalization of -adrenergic receptors
y repeated stimulation by adrenergic agonists) [11]. In a
tudy conducted in 10 subjects with rhinitis medicamentosa
fter 30 days of oxymetazoline, Graf showed a reduction of
ucosal oedema 14 days after stopping the nasal decon-
estants. However, resolution of mucosal oedema could
ot be attributed to withdrawal of the nasal deconges-
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wice daily after stopping oxymetazoline [10]. Another
andomized double-blind study in 20 patients with rhinitis
edicamentosa present for at least 2 years evaluated the
ffect of ﬂuticasone propionate 200g daily versus placebo
or 14 days on nasal congestion, nasal resistance, peak inspi-
atory ﬂow and nasal areas (acoustic rhinomanometry) after
topping nasal decongestants. An improvement of the symp-
oms was observed on D4 with corticosteroids and on D7 with
lacebo. The reduction of nasal oedema, as measured by
asal resistance, was observed on D7 in both groups, but was
igniﬁcantly greater in the 10 subjects treated with topical
orticosteroids [39].
The action of topical corticosteroids on nasal mucosa
ubmitted to nasal decongestants has been evaluated in
n animal model. In a study on 20 guinea-pigs with rhini-
is medicamentosa, Elwany and Abdel-Salaam described
reduction of interstitial oedema by treating the nasal
ucosa with ﬂuticasone propionate 50g per day for 2
eeks after stopping nasal decongestants [29]. Tas et al.
eported similar results after stopping nasal decongestants
y comparing six guinea-pigs treated with mometasone
uroate 50g per day for 14 days, six treated animals
ith isotonic saline and six non-treated animals. A reduc-
ion of oedema and inﬂammatory inﬁltrate was observed
nly in the rhinitis medicamentosa group treated with top-
cal corticosteroids [40]. Studies on human tissues have
lso demonstrated the value of topical corticosteroids to
mprove the epithelial lesions observed in rhinitis, but no
peciﬁc study has been conducted on rhinitis medicamen-
osa. A microscopic study in 46 patients with chronic rhinitis
reated with mometasone furoate 200g/day for 12 months
escribed an increase of ciliated epithelium zones and a
eduction of metaplastic zones [41].
These various studies emphasize the efﬁcacy of topi-
al corticosteroids in the treatment of nasal congestion
nduced by mucosal oedema. Topical corticosteroids appear
o constitute an alternative to nasal decongestants for the
reatment of nasal congestion rather than an antidote for
he treatment of hypothetical rhinitis medicamentosa.
onclusions of the task force after evaluation by
he scoring group
hinitis medicamentosa is an entity with no precise
linical or histopathological criteria in a pathological
ontext of rhinosinusitis. This entity could be more appro-
riately considered to reﬂect the patient’s dependence on
opical decongestants to relieve nasal congestion. In this
etting, the practitioner must review the aetiological work-
p (allergy, irritant and environmental factors) in order to
ore clearly deﬁne this poorly identiﬁed functional nasal
inus disease and propose possible alternative treatments.
anagement of persistent nasal congestion
espite decongestants
ccording to their marketing authorisations, topical or sys-
emic nasal decongestants cannot be used for more than
to 5 days. When the patient reports prolonged use of
asal decongestants, particularly topical nasal deconges-
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must propose alternative treatments. First of all, the clinical
assessment must be repeated to avoid missing a local or sys-
temic aetiology amenable to speciﬁc treatment. The clinical
interview (triggering factors, associated systemic and local
signs), endoscopic examination of the nasal mucosa and
architecture, complementary examinations (allergy assess-
ment, computed tomography with dental evaluation, MRI
when necessary, functional investigations, nasal cytology
according to the context) should allow identiﬁcation of the
various forms of rhinitis and rhinosinusitis.
Alternative treatment options to nasal decongestants can
be proposed. Hypertonic saline has a weak anti-oedema
action, but its clinical value was nevertheless demonstrated
by Garavello et al. in a series of 20 patients treated with 3.0%
hypertonic saline three times daily during the pollen season
(6 weeks) [42] and by Rabago et al. in a series of 40 patients
treated by hypertonic saline as required for 12 months ver-
sus 14 control subjects using isotonic saline [43]. Few studies
are available in the literature allowing comparison of saline
versus decongestants, especially in acute rhinitis. In the con-
text of bacterial rhinosinusitis, Inanli et al. demonstrated
no difference in the degree of improvement of mucociliary
clearance between oxymetazoline, 3.0% or 0.9% saline nasal
irrigation and an untreated control group [44].
Topical corticosteroids have a recognized efﬁcacy in the
treatment of nasal congestion. In a randomized double-blind
study in 967 patients with acute rhinosinusitis, Nayak et al.
showed that topical corticosteroids in combination with
amoxicillin + clavulanic acid were more effective in terms
of improvement of nasal congestion scores than antibiotics
alone by the 4th day [45]. However, no published studies
are available to compare the efﬁcacy of topical cortico-
steroids versus decongestants in the management of nasal
congestion.
Other nasal medications (antihistamines, cromoglycate
sodium, anticholinergics) have no or only a moderate action
on nasal congestion and do not constitute per se an alterna-
tive to nasal decongestants.
Turbinate surgery has a major place in the management
of nasal congestion induced by mucosal oedema. Various
technical modalities (turbinoplasties, radiofrequency, laser,
microresection) can be proposed as a complement to the
alternative treatments described above.
Conclusion
Very few studies have been published on rebound conges-
tion and rhinitis medicamentosa and some of them report
contradictory results. Studies precisely analysing the con-
sequences of prolonged use of nasal decongestants were
conducted on animal models or healthy subjects. Vari-
ous pathophysiological hypotheses have been proposed to
explain the accentuation of congestion induced by nasal
decongestants, but they cannot be extrapolated to the
clinical setting. Other studies are therefore necessary to
speciﬁcally compare patients with rhinitis or rhinosinusitis
treated by various modalities.The analysis conducted by the task force tends to refute
the concepts of rebound congestion and rhinitis medica-
mentosa. Nasal decongestants must nevertheless be used in
a controlled medical setting, in compliance with prescrip-
[ntosa 143
ion guidelines in view of the potentially serious systemic
ffects. In patients with persistent nasal congestion despite
he use of nasal decongestants or accentuation of nasal
ongestion after stopping nasal decongestants, the physi-
ian must review the aetiological work-up of an often poorly
eﬁned nasal sinus disease. Alternative medical and/or sur-
ical treatments must then be proposed.
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